Oral antidepressant formulation

Details Oral antidepressant formulation Oral antidepressant formulation

2004-12-06

2010-02-16

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

C514S649000, C514S651000, C514S647000, C549S462000, C564S428000, C564S308000

Reexamination Certificate

active

07662805

ABSTRACT:
Oral antidepressant formulation comprising an effective antidepressant amount of at least one pharmaceutically acceptable antidepressant active agent and an effective amount lower than 50 mg of acetylsalicylic acid, derivatives of acetylsalicylic acid, or diaspirin, for reducing the onset of antidepressant action.

REFERENCES:
patent: 4594358 (1986-06-01), Hynes
patent: 4650789 (1987-03-01), Pollack
patent: 4866046 (1989-09-01), Amer
patent: 5648396 (1997-07-01), Young et al.
patent: 6245782 (2001-06-01), Serebruany et al.
patent: 6432989 (2002-08-01), Chen
patent: 6440457 (2002-08-01), Edgren et al.
patent: 0 193 355 (1986-09-01), None
patent: 0 193 355 (1986-09-01), None
patent: 2 287 404 (1995-09-01), None
patent: WO 98 50044 (1998-11-01), None
patent: WO 98/50044 (1998-11-01), None
patent: WO 00/28980 (2000-05-01), None
patent: WO 00 59489 (2000-10-01), None
patent: WO 03/103643 (2003-12-01), None
Shad, M. U.; Harvey, A. T.; Lucot, J. B. J. Clin. Psychiatry 1997, 58, 549-550.
Juárez-Olguín, H.; Jung-Cook, H.; Flores-Pérez, J.; Lares-Asseff, I. Neuropsychopharmacology 2000, 22, 100-101.
Sauer et al. (Circulation, Oct. 16, 2001, p. 1894-98).
Sist (J of Pain Symptom Management, vol. 15, Jun. 6, 1998).
Zoloft((http://media.pfizer.com/files/products/uspi—zoloft. pdf#page=43).
MeRec Briefing, “The Management of Depression in Primary Care”.
Clinical Pharmacology of SSRI document (p. 1-10).
“A Blind Panic”, J. Ayuk et al., The Lancet, Lancet Limited, London, GB. vol. 357, No. 9264, Apr. 21, 2001, p. 1262.
“Severe Bleeding Associated with use of Low Molecular Weight Heparin and Selective Seratonin Reuptake Inhibitors”, American Journal of Medicine, vol. 113, No. 6, Oct. 15, 2002, pp. 530-532.
“Adverse Effects of Imipramine are Increased by Interaction with ASA in Depressed Patients”, Neuropsychopharmacology, vol. 22, No. 1, Jan. 2000, pp. 100-101.
“Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastointestinal Bleeding: Population Based Case-Control Study”, BMJ, vol. 319, No. 7217, Oct. 23, 1999, pp. 11-6-1109.

Affiliated with

Also associated with

Rating

Oral antidepressant formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral antidepressant formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral antidepressant formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4222723